Status:

COMPLETED

A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Collaborating Sponsors:

European Society of Surgical Oncology

Conditions:

Liver Metastasis

Colorectal Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

This prospective database has two main objectives; * to evaluate the complication rates, 30-day and 90-day mortality from different surgical strategies for unresectable, borderline resectable or init...

Eligibility Criteria

Inclusion

  • With histologically proven colorectal adenocarcinoma with liver metastasis.
  • With unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer assessed by a clinician or by a multi-disciplinary tumor board (MDT).
  • Unresectable is defined as no possibility of completely resecting all tumor due to size, location or number of deposits.
  • Borderline is defined as potentially operable but technically or biologically more challenging to resect as evaluated by the MDT.
  • Initially unresectable is defined as metastasis that have been down-sized after conversion chemotherapy and evaluated by the MDT to be resectable
  • discussed by a multidisciplinary team before surgery.
  • Participants of the MDT must include at least one liver surgeon, one radiologist and one oncologist. They will determine the resectability of the CRLM according to local practice.
  • With a possibility of a surgical procedure (resection with or without portal vein embolization, intraoperative local ablative technique or a combined approach) assessed during the MDT.
  • Age ≥ 18 years.
  • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion

  • Any psychological, familial, or sociological condition potentially hampering understanding of the research project.
  • Any other malignancy other than in situ carcinoma of the cervix or non-melanoma skin cancer (unless there has been a disease-free interval of at least 5 years)

Key Trial Info

Start Date :

May 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 1 2021

Estimated Enrollment :

219 Patients enrolled

Trial Details

Trial ID

NCT02218801

Start Date

May 1 2015

End Date

February 1 2021

Last Update

May 31 2022

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Innsbruck Universitaetsklinik

Innsbruck, Austria, 6020

2

Der Wiener Krankenanstaltenverbund - Krankenanstalt Rudolfstiftung

Vienna, Austria, 1030

3

University Hosptial Gent

Ghent, Belgium, 9000

4

Aarhus University Hospital

Aarhus, Denmark, 8000